On June 16, Twist Bioscience rose 5.51% in regular trading, trading at $85.14/share, with turnover of $27.86 million, extending its strong momentum from the prior session.

On the news front, Canaccord Genuity initiated coverage with a Buy rating and a $90 price target, well above the analyst consensus target of $73.12 per FactSet data. The $90 target implies approximately 5.6% upside from current levels and has provided a clear near-term catalyst for the stock. The upgraded target marks a notable premium to Wall Street consensus, signaling bullish conviction in the company's growth trajectory.

Twist Bioscience is a synthetic biology platform company that develops silicon-based DNA synthesis technology, serving healthcare, food and agriculture, industrial chemicals, and data storage markets. The stock has gained significant ground from its 52-week low of $23.30, with shares now trading near recent highs.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)